In Vitro Dissolution of Fluconazole and Dipyridamole in Gastrointestinal Simulator (GIS), Predicting in Vivo Dissolution and Drug-Drug Interaction Caused by Acid-Reducing Agents

被引:59
作者
Matsui, Kazuki [1 ,2 ]
Tsume, Yasuhiro [1 ]
Amidon, Gregory E. [1 ]
Amidon, Gordon L. [1 ]
机构
[1] Univ Michigan, Coll Pharm, Ann Arbor, MI 48109 USA
[2] Mochida Pharmaceut Co Ltd, Pharmaceut Res Ctr, Pharmacokinet & Safety Lab, Discovery Res, Shizuoka 4128524, Japan
关键词
dissolution; GIS; BCS; drug-drug interactions; IVIVC; in vivo predictive dissolution methodology; supersaturation; precipitation; dipyridamole; fluconazole; WATER-SOLUBLE DRUGS; ORAL ABSORPTION; GASTRIC PH; WEAK BASES; RELATIVE BIOAVAILABILITY; DOSAGE FORMS; SOLUBILITY; SYSTEM; MEDIA; SUPERSATURATION;
D O I
10.1021/acs.molpharmaceut.5b00135
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Weakly basic drugs typically exhibit pH-dependent solubility in the physiological pH range, displaying supersaturation or precipitation along the gastrointestinal tract, Additionally, their oral bioavailabilities may be affected by coadministration of acid-reducing :agents that elevate gastric pH. The purpose of this study was to assess the feasibility of a multicompartmental in vitro dissolution apparatus, Gastrointestinal Simulator (GIS), in predicting in vivo dissolution of certain oral medications. In vitro dissolution studies of fluconazole, a BCS class I, and dipyridamole, a BCS class II weak bases (class IIb), were performed in the GIS as well as United States Pharmacopeia (USP) apparatus II and compared With the results of clinical drug drug interaction (DDI) studies. In both US? apparatus II and GIS, fluconazole completely dissolved within 60 min regardless of pH, reflecting no DDI between fluconazole and acid-reducing agents in a clinical study. On the other hand, seven-fold and 15-fold higher concentrations of dipyridamole than saturation solubility were observed in the intestinal Compartments in GIS with gastric pH 2.0. Precipitation of dipyridamole was also observed in the GIS, and the percentage of dipyridamole in solution was 45.2 +/- 7.0%. In GIS with gastric pH 6.0, mimicking the coadministration of acid-reducing agents, the concentration of dipyridamole was equal to its saturation solubility, and the percentage of drug in solution was 9.3 +/- 2.7%. These results are consistent with the clinical DDI study of dipyridamole with famotidine, which significantly reduced the C-max and area under the curve. An In situ mouse infusion study combined with GIS revealed that high concentration of dipyridamole in the GIS enhanced oral drug absorption, which confirmed the supersaturation of dipyridamole. In conclusion, GIS was shown to be a useful apparatus to predict in vivo dissolution for BCS class IIb drugs.
引用
收藏
页码:2418 / 2428
页数:11
相关论文
共 46 条
  • [1] A THEORETICAL BASIS FOR A BIOPHARMACEUTIC DRUG CLASSIFICATION - THE CORRELATION OF IN-VITRO DRUG PRODUCT DISSOLUTION AND IN-VIVO BIOAVAILABILITY
    AMIDON, GL
    LENNERNAS, H
    SHAH, VP
    CRISON, JR
    [J]. PHARMACEUTICAL RESEARCH, 1995, 12 (03) : 413 - 420
  • [2] Oral Bioperformance and 21st Century Dissolution
    Amidon, Gregory E.
    Hawley, Michael
    [J]. MOLECULAR PHARMACEUTICS, 2010, 7 (05) : 1361 - 1361
  • [3] [Anonymous], 2000, WAIV VIV BIOAV BIOEQ
  • [4] A dynamic artificial gastrointestinal system for studying the behavior of orally administered drug dosage forms under various physiological conditions
    Blanquet, S
    Zeijdner, E
    Beyssac, E
    Meunier, JP
    Denis, S
    Havenaar, R
    Alric, M
    [J]. PHARMACEUTICAL RESEARCH, 2004, 21 (04) : 585 - 591
  • [5] INCREASED GASTRIC PH AND THE BIOAVAILABILITY OF FLUCONAZOLE AND KETOCONAZOLE
    BLUM, RA
    DANDREA, DT
    FLORENTINO, BM
    WILTON, JH
    HILLIGOSS, DM
    GARDNER, MJ
    HENRY, EB
    GOLDSTEIN, H
    SCHENTAG, JJ
    [J]. ANNALS OF INTERNAL MEDICINE, 1991, 114 (09) : 755 - 757
  • [6] Drug Absorption Interactions Between Oral Targeted Anticancer Agents and PPIs: Is pH-Dependent Solubility the Achilles Heel of Targeted Therapy?
    Budha, N. R.
    Frymoyer, A.
    Smelick, G. S.
    Jin, J. Y.
    Yago, M. R.
    Dresser, M. J.
    Holden, S. N.
    Benet, L. Z.
    Ware, J. A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 92 (02) : 203 - 213
  • [7] Relative bioavailability estimation of carbamazepine crystal forms using an artificial stomach-duodenum model
    Carino, SR
    Sperry, DC
    Hawley, M
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 95 (01) : 116 - 125
  • [8] Relative Bioavailability of Three Different Solid Forms of PNU-141659 as Determined with the Artificial Stomach-Duodenum Model
    Carino, Stephen R.
    Sperry, David C.
    Hawley, Michael
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2010, 99 (09) : 3923 - 3930
  • [9] Predicting Intestinal Precipitation-A Case Example for a Basic BCS Class II Drug
    Carlert, Sara
    Palsson, Anna
    Hanisch, Gunilla
    von Corswant, Christian
    Nilsson, Catarina
    Lindfors, Lennart
    Lennernas, Hans
    Abrahamsson, Bertil
    [J]. PHARMACEUTICAL RESEARCH, 2010, 27 (10) : 2119 - 2130
  • [10] Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Fluconazole
    Charoo, Naseem
    Cristofoletti, Rodrigo
    Graham, Alexandra
    Lartey, Paul
    Abrahamsson, Bertil
    Groot, D. W.
    Kopp, Sabine
    Langguth, Peter
    Polli, James
    Shah, Vinod P.
    Dressman, Jennifer
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2014, 103 (12) : 3843 - 3858